Number of voting rights and shares as of december 31, 2016

09 Jan 2017 17:50 CET

Total number of voting rights and shares

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority).

“Including 1,500,000 new shares in accordance with the contract of Equity line financing concluded with Kepler Cheuvreux on November 20^th2014, for a total amount of 1,065,000€. A shareholder holding 1.0% of the Company share capital (November 30^th, 2016) would be reduced to approximately 0,97%  of the capital on non-diluted basis”

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

NEOVACS – Investor Relations

Charlène Masson

+33 (0)1 53 10 93 00

cmasson@neovacs.com

Investor Relations / Financial Communications –Life Science Advisors

Chris Maggos

chris@lifesciadvisors.com

Connect_neovacs_regulated-information-reglementee31122016.pdf